Jay D. Kranzler, M.D., Ph.D. - Chief Executive Officer and Chairman of the Board
Dr. Kranzler was appointed Chief Executive Officer of Cypress in December 1995. During his tenure, Cypress has successfully raised $226 million in new funding, received FDA approval to market the Company's former product, the PROSORBA® column for rheumatoid arthritis, and executed multiple license agreements. In 2001, in an effort to change the direction of the company, Dr. Kranzler initiated research into novel therapeutic areas for fibromyalgia syndrome which resulted in the licensing of Cypress' lead product, milnacipran. Under his direction, Cypress has completed a successful Phase III program and has filed a NDA with the FDA. In addition, Dr. Kranzler was instrumental in the execution of a licensing agreement with Forest Laboratories thereby increasing shareholder value and positioning the company to become a leader in developing products for the treatment of functional somatic syndromes. Previously, Dr. Kranzler served as President, Chief Executive Officer and a Director of Cytel Corporation where he diversified Cytel's technology base, raised $73 million through public offerings and acquired two technology companies, Glycogen and Receptor Laboratories, to augment the company's technology base. Under his leadership, Cytel secured five strategic alliances with major pharmaceutical companies - Upjohn, Sandoz, Sumitomo, Takara and Schwartz Pharma - which raised more than $150 million in research and development funding and equity investments.

Dr. Kranzler founded Sequel Therapeutics in 1992 and served as President, Chief Executive Officer and Chairman of the Board for this joint venture with The Scripps Research Institute, which is now wholly owned by Cytel. He also co-founded Glytec Corporation in 1989 and served as President, Chief Executive Officer and Director until its acquisition by Cytel in 1990.

From 1985 to January 1989, Dr. Kranzler was a management consultant with the international consulting firm McKinsey & Company, where he worked with many of the world's leading pharmaceutical and technology companies conducting technology assessments, optimizing operating performance, evaluating research and development opportunities and structuring mergers and acquisitions.

At Yale University, Dr. Kranzler earned his M.D. with a concentration in Psychiatry and earned his Ph.D. in Pharmacology for his thesis work on biochemical gender differences in the brain. He graduated summa cum laude from Yeshiva University, where he was a Belkin Scholar. Dr. Kranzler is currently a lecturer at The Rady School of Business of the University of California- San Diego, where he serves as Executive in Residence.

Sabrina Martucci Johnson – Executive Vice President, Chief Operating Officer and Chief Financial Officer
Sabrina Martucci Johnson was appointed Chief Operating Officer in January 2008 and previously served as our Chief Business Officer.  Ms. Johnson has served as our Chief Financial Officer since April 2002. Ms. Johnson joined the Company in August of 1998 and held various positions from 1998 through 2002, including Vice President Marketing. Johnson previously held marketing and sales positions with Advanced Tissue Sciences and Clonetics. Ms. Johnson has an MBA from the American Graduate School of International Management (Thunderbird) and a MSc. in Biochemical Engineering from the University of London, and a BSc. in Biomedical Engineering from Tulane University. Johnson began her career in the biotechnology industry as a research scientist with Baxter Healthcare, Hyland Division.

Michael J. Walsh– Executive Vice President and Chief Commercial Officer
Mr. Walsh became our Executive Vice President and Chief Commercial Officer in March 2008. Prior to Cypress, Mr. Walsh founded Proprius Pharmaceuticals, Inc. in 2005 and was its President and CEO from its founding until we acquired Proprius in March 2008. Prior to establishing Proprius, Mr. Walsh was a founder and Executive Chairman at Prometheus Laboratories, Inc., a specialty pharmaceutical company, from 1995 to 2005. Prior to founding Prometheus Laboratories, Inc., Mr. Walsh was with Quidel Corporation in various senior executive roles, including Director of Worldwide Marketing and Business Development, and Director of European Operations. Prior to Quidel he was Manager of Therapeutic Operations at La Jolla Pharmaceutical Company. Mr. Walsh serves on the Board of Directors of Kanisa Pharmaceuticals, Inc., and as Chairman of the Board of Oculir, Inc. Mr. Walsh has a Bachelor of Science degree from the University of Notre Dame and an M.B.A. from Pepperdine University.

R. Michael Gendreau, M.D., Ph.D. –Vice President Clinical Development, Chief Medical Officer
Dr. Gendreau is the longest serving member of the Cypress management team, having joined the company in 1994. He has 20+ years of experience in the development, clinical evaluation and commercialization of drug, biologic, medical device, and diagnostic products. Dr. Gendreau led the team that designed and managed Cypress' successful Phase III pivotal trial program and subsequent FDA submissions (1996-1999) for the Company's former rheumatoid arthritis treatment, the Prosorba column. With the change in focus of Cypress to fibromyalgia and related functional somatic syndromes, he has been responsible for the company's current clinical programs evaluating milnacipran as a pharmacological treatment for the signs and symptoms of the fibromyalgia syndrome. From 1991 to 1994, he served in various senior management roles in research, clinical development and regulatory affairs for Microprobe, Inc. of Seattle, WA, a biotechnology company developing oligonucleotide technology for diagnostic and therapeutic applications. From 1988 to 1991, Dr. Gendreau served as Vice President of research and development for Source Scientific Systems, a developer and manufacturer of OEM medical devices. From 1981 to 1988, Dr. Gendreau served as manager of world wide Health Care Technology for the Battelle Memorial Institute of Columbus, OH. At Battelle, he served as a medical technology consultant, managed scientific and clinical development programs globally, supervised reimbursement and policy analysis, and developed diagnostic products. He also concurrently while at Battelle spent five years as Principal Investigator of the "National Center for Biomedical Spectroscopy", an NIH funded center of excellence based on findings from Dr. Gendreau's doctoral research at Ohio State. Dr. Gendreau received his B.S. degree in Chemistry from Ohio University, and his M.D./Ph.D. degree in medicine and pharmacology from the Ohio State University, where he graduated summa cum laude.

Srinivas G. Rao, M.D., Ph.D. – Chief Scientific Officer
Dr. Rao joined Cypress in August 2000 and has worked in a variety of areas, including scientific assessment of potential in-licensing compounds, business development, preclinical study design, design and execution of Cypress’ genomics program, and development of Cypress’ intellectual property program for milnacipran. Prior to Cypress, Dr. Rao worked as a free-lance medical electronics consultant while completing his combined M.D. and Ph.D. program at Yale Medical School. His Ph.D. research focused upon central nervous system neuropharmacology and took place in the laboratory of Dr. Patricia Goldman-Rakic, a world-renowned expert in working memory and pre-frontal function. Upon completion of the M.D. degree, Dr. Rao completed an internship in Internal Medicine at Yale-New Haven Hospital. Dr. Rao holds both an M.S. and B.S. from Yale University in Electrical Engineering.

Denise L. Wheeler– General Counsel
Denise L. Wheeler was appointed as our General Counsel in July 2007 and previously served as our Vice President of Business and Legal Affairs and Corporate Secretary since February 2004. Prior to joining Cypress, from September 1997 to February 2004, she was an associate in the Cooley Godward business department. Ms. Wheeler practiced primarily in the areas of corporate finance and general corporate representation of life sciences companies. Ms. Wheeler represented both privately-held and public companies in the life science industries in a wide range of transactions, including public offerings, private placements, mergers and acquisitions and technology licensing. Ms. Wheeler received her J.D., magna cum laude, from the University of San Diego School of Law in 1997. She completed a Bachelor's degree, cum laude, at Old Dominion University in 1991. Ms. Wheeler is a member of the State Bar of California, the American Bar Association and the San Diego County Bar Association. Ms. Wheeler also serves on the board of Neighbor Help, a non profit charitable organization.